Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIRACAN: atezolizumab + tiragolumab basket trial in solid tumors
NL-OMON53466Phase 2Recruiting
- Sponsor
- Medische Oncologie
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab and tiragolumab in Nonhematologic neoplasms, head and neck squamous cell carcinoma (HNSCC), microsatellite instability-high cancer and 1 more, sponsored by Medische Oncologie. Primary endpoints: Pathologic response rate, Objective response rate by RECIST 1.1 and 1 more. Started Oct 2023; status: recruiting.
02
Drugs
atezolizumabtiragolumab
03
Conditions
Nonhematologic neoplasmshead and neck squamous cell carcinoma (HNSCC)microsatellite instability-high cancermelanoma
Beyond the preview
Go deeper on NL-OMON53466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53466.